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Background: Admission to an emergency department (ED) is a key vulnerable moment when patients are at
increased risk of medication discrepancies and medication histories are an effective way of ensuring that fewer
errors are made. This study measured whether a pharmacist-acquired medication history in an ED focusing on a
patient’s current home medication regimen, and available to be used by a doctor when consulting in the ED,
would reduce the number of patients having at least 1 medication discrepancy related to home medication.
Methods: This multicentre, double-blind, randomised, controlled parallel-group study was conducted at 3 large
teaching hospitals. Two hundred and seventy participants were randomly allocated to an intervention (n = 134) or a
standard care (n = 136) arm. All consecutive patients >18 years old admitted through the ED were eligible. The
intervention consisted of pharmacists conducting a standardised comprehensive medication history interview
focusing on a patient’s current home medication regimen, prior to being seen by a doctor. Data recorded on the
admission medication order form was available to be used by a doctor during consultation in the ED. The
admission medication order form was given to doctors at a later stage in the control arm for them to amend
prescriptions. The effect of the intervention was assessed primarily by comparing the number of patients having at
least 1 admission medication discrepancy regarding medication being taken at home. Secondary outcomes
concerned the characteristics and clinical severity of such medication discrepancies.
Results: The intervention reduced discrepancies occurring by 33% (p < 0.0001; 0.1055 odds ratio, 0.05-0.24 95%
confidence interval), despite recall bias. Regarding total discrepancies, omitting medication occurred most
frequently (55.1%) and most discrepancies (42.7%) were judged to have the potential to cause moderate discomfort
or clinical deterioration.
Conclusions: A pharmacist-acquired medication history in an ED focusing on a patient’s current home medication
regimen available to be used by a doctor at the time of consulting in the ED reduced the number of patients
having at least 1 home medication-related discrepancy.
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Medication histories are an effective way of contributing
to a decrease in hospital admission-related medication
discrepancies [1]. An accurate history of medication use
is an important part of patient appraisal on admission
[2]. The completeness of such medication use history
depends on different factors concerning a particular
patient, including the time available for interview, language
barriers, illness severity, cognitive status and a patient’s
familiarity with his or her medication regimen [3]. A
pharmacist’s involvement as part of the care-team in an
admission clinic can improve patient safety [4]. Studies
have shown that a pharmacist-acquired medication history
is more comprehensive than that obtained by other health
professionals [5-7], as pharmacists represent an ideal
resource because they possess the pertinent knowledge
and training [7-12].
Unintentional medication discrepancies frequently occur
on admission to an emergency department (ED); up to
60% of patients admitted to an in-patient unit have at least
1 unintended medication discrepancy regarding their home
medication regimen and the admission orders [2,3,12]. The
most common error lies in omitting a medication being
taken at home [11,12]; this problem concerns the multi-
disciplinary health-care team’s difficulty in accessing a
complete and accurate home medication list. Hospital
admission is thus an interface in the care process regard-
ing a potential gap in the transfer of medication-related
information [4].
The Joint Commission on Accreditation of Healthcare
Organizations has defined medication reconciliation
(MedRec) as the process of comparing a patient’s medica-
tion orders to all of the medications that such patient has
been taking. An accurate and up-to-date medication
history is considered an essential component of safe and
effective medical practice. MedRec is aimed at avoiding
medication errors such as omissions, duplications, dosing
errors or drug interactions. It should be made during
every care stage/transition where new medications are
ordered or existing orders may be rewritten. Transitions
in care include changes in setting, service, practitioner or
care level [13].
It has been hypothesised that a hospital involving the
pharmacist as part of a multidisciplinary team in the ED
for supporting medication being prescribed on admission
and incorporating MedRec will prevent and reduce home
medication-related discrepancy frequency on admission.Aim
This study’s primary objective was to evaluate whether a
pharmacist-acquired medication history in an ED focusing
on a patient’s current home medication regimen, and
available to be used by doctor at the time of consulting inan ED, would reduce the number of patients having at least
1 medication discrepancy related to home medication.
Methods
Trial design
A multicentre, double-blind, randomised and controlled
parallel-group trial study was conducted in accordance
with the provisions of the Declaration of Helsinki (1996)
and Good Clinical Practice (GCP) guidelines. All partici-
pants gave their written informed consent. The trial was
registered as Current Controlled Trial ISRCTN63455839.
The allocation ratio for the intended numbers of par-
ticipants in each comparison group was 1:1. The report
involved using consolidated standards of reporting trials
(CONSORT) [14].
Testing the survey questionnaire
The procedure for validating data collection forms and
standardising the admission medication order form in-
volved 30 patients (ten participants per hospital). Particular
emphasis was placed on examining whether the researchers
were able to complete the questionnaires in full without
difficulty (i.e. responding to the patients’ answers) and the
length of time required for doing so. This was verified using
a simulated exercise.
The whole team received formal training on how to
complete a MedRec form, including a description of
data-collection tools and procedures. Two pharmacists per
hospital independently filled out the forms, different per-
centages of agreement being obtained between hospitals
(100% Fundacion Cardio Infantil, 60% Hospital Samaritana
and 50% at Hospital San Carlos). Differences and the team
were evaluated, agreement being reached by consensus.
Participants
The study was conducted from October 26th to November
30th 2012 at 3 large teaching hospitals in Bogota, Colombia.
All consecutive patients (18 years or older) who had been
admitted to an ED, taking at least one medication or had
been prescribed a minimum of one prescription medication
before admission, who had been assessed as triage I and II
on admission and who had been hospitalised for at least
24 hours were eligible for inclusion. Patients were classified
as triage I or II (triage I meant patients having ventilator,
haemodynamic and neurological stability, suffering a con-
dition representing a potential threat to life or loss of limb
or organ if they were not to have received prompt medical
intervention; triage II referred to when patients had a con-
dition which might have progressed to becoming serious
and were judged as requiring emergency assessment and
were likely to require inpatient treatment) [15,16]. Patients
were enrolled on weekdays, weekends and holidays (i.e. 24
hours per day). Patients were excluded if they had been
scheduled for discharge on the same day, were not able to
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unable to communicate due to language difficulties, were
under psychiatric care, had a medical record of dementia
or confusion and/or were unable to give their consent.
Pharmacist intervention
The intervention consisted of a pharmacist-acquired medi-
cation history in an ED focusing on a patient’s current
home medication regimen documented on the admission
medication order form (F1) which was available to be used
by a doctor when consulting in an ED. Doctors verified the
data with patients and indicated which home medications
were to be reordered, suspended or discontinued. This
resulted in an accurate and comprehensive history of a
patient’s current home medication regimen, called medi-
cation order form verified with patient (F1V).
On admission to an ED
One team of research pharmacists employed for this study
conducted a standardised, comprehensive medication
history interview, focusing on current home medication
regimen for all patients included in the study, prior to
being seen by a doctor. A thorough history of all regular
medication use (prescription, non-prescription, nutritional
supplements, vitamins, over-the-counter, herbal, vaccines,
drugs and diagnostic contrast or radioactive agents, paren-
teral nutrition, blood products and intravenous solutions)
was ascertained using all the following sources of informa-
tion: patient and/or caregiver interview, a check of the last
prescription and an inspection of the medicines carried
by a patients (i.e. in the ED). Pharmacists conducted
telephone interviews with caregivers or family members
when patients were unable to clarify their medication regi-
men. Relevant demographic and medical data was collected
and documented on F1.
F1 was used by a doctor during consultation for issuing
prescriptions in an inpatient ED (just for the intervention
group). By checking boxes, the doctor verified with a
patient and indicated which home medications were to be
reordered, suspended or discontinued (F1V). For patients
who were in the control arm, F1 was given to the doctors
at a later stage for them to amend prescriptions.
Follow-up medication
Another team of regular pharmacists blinded to interven-
tion status in the hospitals being studied reviewed each
medical chart regarding all the drugs prescribed 24
hours after having been admitted to an ED. The data
came from various information sources including a
patient’s computerised hospital medical record, F1, the
physician-recorded medication history, the nurse-recorded
medication history, interviews with patients, medication
administration records and demographic information. The
pharmacist also attempted to verify with the patient if anymedication changes had been made since their clinical
assessment (i.e. on admission to an ED). This was
documented in the list of medications prescribed by a
doctor during 24 hours in an ED (F2).
Medicine reconciliation
MedRec was used for comparing a patient’s current home
medications to medications prescribed 24 hours after
having been admitted to an ED to see whether patients’
home medications were also prescribed by a doctor in an
ED. This was done by an independent team (pharmacist
and doctor blinded to intervention status) and took place
the day after admission.
If incongruity was detected and the reason had not
been documented in the medical record, this was clarified
with the medical team and patient. External evaluation
was made by the chief of each hospital’s ED after MedRec
had ended; this person then resolved any discrepancies
with each doctor. Following MedRec, further medication
required doctors to write separate medication orders
(see Figure 1).
Standard group
Patients in the control group received standard care; this
included doctors documenting medication histories in
admission notes and nurses reviewing medication orders
for appropriateness. Doctors wrote in-patient orders during
consultation without having access to F1. The medication
information was entered on each medical chart forming
part of a hospital’s electronic health records. Pharmacists
were not routinely involved in documenting patients’
admission medication histories; this function is primarily
the admitting resident doctor or medical student’s respon-
sibility at the institutions involved in the present study.
Outcomes
The effect of the intervention was assessed by comparing
the number of patients having at least 1 admission medi-
cation discrepancy regarding medication being taken at
home. Secondary outcomes concerned the characteristics
and clinical severity of such medication discrepancies.
Admission discrepancies were defined as any medication
clarification related to current home medication made
whilst being cared for in an ED. They could have been
associated with any of the following: drug, dosage, fre-
quency, administration route, appropriateness of restarting
medication, therapeutic duplicity and/or medications
lacking indication. Discrepancies were identified using a
systematic approach (i.e. MedRec).
The clinical severity of medication discrepancies was
independently assessed by two clinical pharmacists blinded
to the patient data collection forms; they classified each
type of medication discrepancy according to its potential
to cause harm, the degree of effect being adapted from the
Figure 1 Study design.
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resolved by discussion and consensus was reached for all
discrepancies. The degree of effect for each medication
discrepancy was defined as follows. Class 1 discrepancies
were classified as being those unlikely to cause patient
discomfort or clinical deterioration, Class 2 those having
the potential to cause moderate discomfort or clinical
deterioration and Class 3 discrepancies had the potential
to result in severe discomfort or clinical deterioration.
Allergies were identified using part of F1; this only
focused on requiring information about food and drug
allergies and type of allergic reaction.
Interactions were identified using the Drug Interaction
Checker; it also displayed any interactions between the
drugs being chosen and food and explained the mechanism
for each drug interaction (interaction significance level
could have been major, moderate or minor) [17].
Sample size
A multicentre study was conducted. The baseline number
of patients having at least 1 medication discrepancy was
30%; this was used for calculating sample size. A 2-tailed
Chi square test (α = 0.05 and ß = 0.20) gave a minimum
enrolment of 120 patients in each arm for the study to
have sufficient power, assuming that the intervention arm
would reduce the number of patients having at least 1
of admission medication discrepancy related to home
medication by 50%. This was increased to 135 patients in
each group to compensate for dropouts. The reference
values used for establishing sample size were taken from
previous studies [4].
Randomising
Patients and doctors were randomly assigned to the inter-
vention or standard care arm using random-number com-
puter generation in Microsoft Excel. Allocation by each
randomisation manager was daily and depended on the
number of patients, doctors and residents per shift.
Randomisation involved 3 blocks of 90 numbers, one per
each hospital. The allocation group could have equated odd
and even numbers for interventions A and B, respectively,
to ensure equal allocation.
Allocation concealment mechanism
The combined coded numbers concerning intervention al-
location were concealed in sequentially-numbered, sealed,
opaque envelopes and kept by the clinical trials group at
the Universidad Nacional de Colombia (UNALCO, Bogota).
The assignments were also concealed in sequentially-
numbered containers, according to the allocation sequence.
It was ensured that all envelopes were numbered in
advance and that they were equal in weight and similar in
appearance. It was guaranteed that the envelopes were
opened sequentially and only after a participant’s nameand other details had been written on the assignation list.
Stringent procedures were used for ensuring enrolment
before randomisation. Two exactly similar copies of the
randomisation list were prepared; one was used by the
randomisation manager and the other copy was kept
under lock and key by the emergency coordinator. The
envelope was made of cardboard to render it impermeable
to intense light. An audit trail was created.Implementation
Each block of 90 numbers was sent from the central office
to a person who acted as the randomisation manager in
each hospital. A nurse (epidemiologist) not involved in
caring for the trial patients and independent of the site
investigator was responsible for trial allocation and
record-keeping (i.e. the randomisation manager). The
randomisation schedule was thus concealed from all care
providers, ward doctors and other research personnel. The
pharmacists worked in different shifts to obtain the records.
The MedRec procedure was adapted and standardised from
the Institute for Healthcare Improvement “toolkit” that
provides extensive details on where and how to reconcile
medications, how to implement procedures and provides
sample flow-charts, algorithms and forms [18,19].Blinding
No patient, nurse, doctor, investigator or any other medical
or nursing staff in an ED was aware of the intervention
assignments for the duration of the study; neither the
patients nor the doctors could distinguish between the
intervention and control group. All patients were inter-
viewed by pharmacists. They were supplied with uniforms
and ID cards similar to those of the hospital workers; they
were involved in admission work.
The doctors were assigned to receive only patients in
the intervention or control group during their shifts to
ensure blinding. The randomisation manager placed an
F1 into the medical chart so that a doctor would think
that it was regular documentation. If they asked about the
form, the randomisation manager told them it concerned
an on-going pilot study. The randomisation manager was
instructed to report any suspected breach of the masking
procedures.
The forms used were made to look the same as the
forms used in the hospitals, the logo, colours and fonts
being exactly alike so it seemed that the doctor was
filling in just another new form. All statistical analysis
involved maintaining the masking. Analysis was completed
before the randomisation code was broken at the end of
the completed trial. Each researcher sent the data online
via an information system link provided by the statistics
office. All records were checked.
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An exact X2 test was used to investigate differences in
the percentage of patients having at least 1 medication
discrepancy between treatment groups; baseline charac-
teristics were compared using the exact X2 test as appro-
priate. Multivariate logistic regression analysis was used to
investigate predictors of at least 1 medication discrepancy.
Comparisons were made between the intervention and
control groups by logistic regression analysis for binary
responses using odds ratios (Cox proportional hazards
model). Linear regression analysis was used for continuous
responses using differences and Poisson regression analysis
for incidences; fractions were used for comparisons. All
tests were 2-tailed and a test result was deemed statistically




The 270 patients who were randomised and selected by
consecutive sampling for the study (134 intervention and
136 controls) were cared for by each of the 3 randomised
teams and by 91 admitting doctors. Twenty-two patients
(12 interventions and 10 controls) had been assessed and
ranked incorrectly during triage and were discharged on
the same day. They were excluded from the main study
analysis and the most common reason for patient exclusion
was non-adherence to protocol because they had been
discharged before their 24-hour follow-up. Six patients
(5 interventions and 1 control) voluntarily decided to
leave the hospital and seek care at another hospital and
they were consequently excluded. Figure 2 shows the flow
of participants throughout the trial.
Baseline data
Table 1 give patients’ baseline demographic and clinical
characteristics regarding the intervention and standard
care arms. There were no statistically significant differences
between both treatment arms. Patient characteristics in the
2 study arms were similar.
Effect of the intervention
For the primary end point, 117 (93.6%) of the 125 patients
had at least 1 admission medication discrepancy in the
standard care arm, compared to 71 (60.7%) of 117 patients
in the intervention care arm (p < 0.0001; 0.1055 odds ratio
(OR), 0.05-0.24 95% confidence interval (CI)). The overall
discrepancy rate was 3.35 per patient (SD 3.32); it was
4.23 (SD 3.26) in the standard care arm and 2.43 (SD 3.14)
in the intervention arm.
Doctor/pharmacist agreement on identifying allergies
was also studied using Cohen’s association coefficient
(K = 0.434; 95%CI; p < 0.001), showing a moderate level
of agreement between both types of reviewer as thepharmacists identified 48 patients suffering allergies and
the doctors 23.
The association between discrepancies and baseline
patient characteristics was also evaluated (Table 2). Increas-
ing age was a weak predictor of having a medication dis-
crepancy only in the univariate model (1.02 OR, 1.01-1.04
95%CI). Regarding the study population’s clinical character-
istics in the univariate model, the number of medications
taken at home (1.45 OR, 1.25-1.72 95%CI; p = 5.51E-06)
and number of co-morbidities (1.56 OR, 1.14-2.19 95%CI;
p = 0.00734) increased the risk of discrepancy most whilst
healthcare-service settings regarding ED admission and
intervention significantly decreased such risk.
Patients’ clinical conditions accounted for the decrease
in discrepancies revealed by multivariate analysis. Due to
the association between variables, the number of medicines
being taken increased discrepancy risk (1.62 OD, 1.31-2.06
95%CI; p = 3.12E-05) while the healthcare-setting regarding
ED admission decreased discrepancy risk (0.26 OR,
0.07-0.89 95%CI; p = 0.0366). Pharmacist intervention was
also associated with an increased effect concerning reducing
discrepancy risk (0.04 OR, 0.01-0.11 95%CI; p = 1.16E-09).
The effect of such intervention remained statistically sig-
nificant (p < 001) after adjustment for all other predictor
variables.
Medication discrepancy characteristics and clinical
severity
The most common discrepancy concerned the omission
of home medication being reordered (55.1%); 66.3% of
omission discrepancies were in the standard arm and
34.3% in the intervention arm. This was followed by
incorrect or omitted dose and being slow to restart drug
therapy. Over-the-counter-medicines were omitted in 100%
of the cases. Other types of medication discrepancies are
summarised in Table 3. The two most common classes
involved in discrepancy were cardiovascular agents (23.6%)
and alimentary tract and metabolism agents (17.0%).
A higher percentage of patients who were interviewed
by pharmacists were identified as using home medication
(457, 82.8%) compared to those in the standard care arm
(255, 42.5%) regarding 1,169 medications consumed by
patients in the study.
The likelihood that a medication discrepancy might
have caused discomfort and/or clinical deterioration was
appraised and categorised. Fleiss’ kappa coefficient was
used (κ = 0.829; p = 0) [20]. There was very good agreement
among evaluators in judging the potential clinical effect of
medication discrepancy.
Most discrepancies (42.7%) were judged to have the
potential to cause moderate discomfort or clinical deterior-
ation; 33.4% of the discrepancies were deemed unlikely to
cause harm and 23.9% were judged to have the potential to
cause severe discomfort or clinical deterioration (Table 4).
Figure 2 Participant flowchart.
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8.7% major, 68.2% moderate and 23.1% minor. The major
interactions were associated with the inflammatory, blood
and central and peripheral nervous systems. One hundred
and fourteen patients had at least one interaction, 63.2% in
the standard care arm and 36.8% in the intervention arm.
Intervention reduced the occurrence of interactions.
Assessing the process
All discrepancies were communicated to the chief of each
hospital’s ED after data collection had ended; this person
then resolved discrepancies with each doctor. Our results
confirmed that pharmacists’ interventions were well-received
by ED doctors, having a 96% acceptance rate. The result
was unknown in only 4% of the suggested actions.
The median time required for each pharmacist to
complete the medication record for each patient was 29.5minutes (IQR = 22.25 minutes, minimum 6 minutes, max-
imum 135 minutes).
Discussion
Several publications [5,9,21,22] have demonstrated that
pharmacist-acquired medication histories in an ED have
led to reducing discrepancies; our results were consistent
with previous studies. The effect of the intervention re-
duced discrepancies occurring by 33% (p < 0.0001; 0.1055
OR, 0.05-0.24 95%CI), despite patient recall bias.
Although every attempt was made to interview patients
or family members and inspect prescription vials or
medication bottles for all study subjects, medications
could not be inspected in many cases; the interviewer/
researcher relied on written medication lists provided by
the patient, caregiver or family or calling his/her house in
such situations.
Table 1 The study population’s baseline demographic and clinical characteristics
Characteristics All groups Control Intervention Value p–value
242 (100) 125 (51.65) 117 (48.35)
Age, mean ± SD 59 ± 19 58 ± 20 59 ± 18 −0.5355a 0.5928
Gender 0.2233b 0.6365
Female 140 (57.9) 70 (56.0) 70 (59.8)
Male 102 (42.1) 55 (44.0) 47 (40.2)
Educational level 0.0572b 0.9964
No schooling 19 (7.9) 10 (8.0) 9 (7.7)
Elementary school 105 (43.4) 54 (43.2) 51 (43.6)
High school 81 (33.5) 43 (34.4) 38 (32.5)
Undergraduate 33 (13.6) 17 (13.6) 16 (13.7)
No information 4 (1.7) 1 (0.8) 3 (2.5)
Social status* 6.7379b 0.08074
Strata 1 (lowest level) 135 (82.3) 59 (76.6) 76 (87.4)
Strata 2 (low - medium) 22 (13.4) 12 (15.6) 10 (11.5)
Strata 3 (medium) 2 (1.2) 1 (1.3) 1 (1.1)
Strata 6 (highest level) 5 (3.1) 5 (6.5) 0 (0.0)
Teaching hospitals 5.1145b 0.07752
Fundacion Cardio Infantil 82 (33.9) 36 (28.8) 46 (39.3)
San Carlos 78 (32.2) 48 (38.4) 30 (25.6)
La Samaritana 82 (33.9) 41 (32.8) 41 (35.1)
No. of hospitalisations, median (IQR, min, max) 0 (1, 0, 12) 0 (1, 0, 10) 0 (1, 0, 12) −0.2168a 0.8285
No. of co-morbidities, median (IQR, min, max) 1 (2, 0, 4) 1 (2, 0, 4) 1 (1, 0, 4) 0.4219 a 0.6735
Type of comorbidity 11.6316b 0.392
Arthritis/osteoporosis 16 (5.5) 11 (7.2) 5 (3.6)
Malignant diseases 12 (4.1) 4 (2.6) 8 (5.7)
Cardiovascular disorder 90 (30.8) 47 (30.7) 43 (31.0)
Diabetes mellitus 22 (7.5) 12 (7.9) 10 (7.2)
Epilepsy/Parkinson’s disease 10 (3.4) 7 (4.6) 3 (2.2)
Pulmonary disease 18 (6.2) 13 (8.5) 5 (3.6)
Gastrointestinal disease 15 (5.2) 7 (4.6) 8 (5.8)
Hypertension 14 (4.8) 6 (3.9) 8 (5.8)
Hypothyroidism 22 (7.5) 8 (5.2) 14 (10.0)
Metabolism disease 18 (6.2) 8 (5.2) 10 (7.2)
Urinary infection 15 (5.1) 7 (4.6) 8 (5.7)
Other 40 (13.7) 23 (15.0) 17 (12.2)
No. of medicines, median (IQR, min, max) 4 (4, 1, 12) 4 (4, 1, 16) 4 (4, 1, 14) −0.3299a 0.7418
Medicine group 17.208b 0.3066
Anti-infective for systemic use 39 (3.7) 15 (2.8) 24 (4.6)
Anti-inflammatory drugs 60 (5.6) 32 (5.9) 28 (5.4)
Cardiovascular system 252 (23.6) 130 (23.9) 122 (23.3)
Alimentary tract and metabolism 194 (18.2) 102 (18.8) 92 (17.6)
Systemic hormonal preparations 31 (2.9) 12 (2.2) 19 (3.6)
Respiratory system 65 (6.1) 33 (6.1) 32 (6.1)
Blood and blood-forming organs 93 (8.7) 51 (9.4) 42 (8.0)
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Table 1 The study population’s baseline demographic and clinical characteristics (Continued)
Nervous system 168 (15.7) 90 (16.5) 78 (14.9)
Vitamins and nutrients 39 (3.7) 21 (3.7) 18 (3.4)
Herbal medicine 21 (2.0) 7 (1.3) 14 (2.7)
Over-the-counter medicine 75 (7.0) 37 (6.8) 38 (7.3)
Other 30 (2.8) 14 (2.6) 16 (3.1)
Allergic reaction 0b 1
No 194 (80.2) 100 (80.0) 94 (80.3)
Yes 48 (19.8) 25 (20.0) 23 (19.7)
No. of interactions
Minorc, median (IQR, min, max) 1 (0, 1, 3) 1 (0, 1, 3) 1 (0, 1, 2) −0.3943 0.6942
Moderated, median (IQR, min, max) 1 (1, 1, 7) 1 (1, 1, 7) 1 (1, 1, 3) 0.9524 0.3416
Majore, median (IQR, min, max) 1 (0, 1, 4) 1 (0, 1, 2) 1 (0, 1, 4) −1.4242 0.1787
Abbreviations: at student; bChi-square; SD (standard deviation). IQR, interquartile range; min, minimum; max, maximum. * Social status is not important data during
the interview on admission to the ED at the San Carlos teaching hospital.
cMinor: Minimal clinical significance, involving minimising risk, assessing risk and considering an alternative drug, taking steps to circumvent interaction risk and/
or instituting a monitoring plan.
dModerate: Moderate clinical significance, usually avoiding combinations, being used only in special circumstances.
eMajor: High clinical significance, avoiding combinations; the risk of the interaction would outweigh the benefits.
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intervention arm still had at least 1 ED admission medica-
tion discrepancy related to home medication. Emphasis
was placed on patients reporting the use of at least 1 medi-
cation during ED admission. Error rates may have differed
regarding services other than admission or among patients
taking more than 1 medication. Our results were consist-
ent with previous studies [21,22] which have reported that
medication discrepancies when being admitted to an ED
are frequent and clinically significant. Omission regarding
over-the-counter medications in our study was 100%.Table 2 Association between patients’ baseline characteristic
Characteristics Univariate log
Odds ratio (95%C
Age 1.02 (1.01 - 1.04)
Being female 1.37 (0.74 - 2.52)
Educational level
No schooling 0.83 (0.20 - 3.69)
Elementary level 0.77 (0.26 - 1.98)
High school level 0.70 (0.23 - 1.85)
Emergency department (Teaching hospitals)
San Carlos 0.43 (0.18 - 0.98)
La Samaritana 0.32 (0.14 - 0.70)
Number of hospitalisations 1.18 (0.93 - 1.69)
Allergic reaction 1.55 (0.71 - 3.79)
Number of comorbidities 1.56 (1.14 - 2.19)
Number of home medications 1.45 (1.25 - 1.72)
Intervention 0.11 (0.04 - 0.23)
Abbreviations: CI, confidence interval.Obtaining medication history can be challenging.
One study has reported that unintentional medication
discrepancies were more often due to errors in recording
medication history than errors reconciling the history with
medication orders. It also reported that relying on family
members or caregivers as sources of medication informa-
tion represented a risk factor [23].
Our study incorporated MedRec when being admitted
to an ED. It has proved useful for improving patient
safety by reducing medication discrepancies before harm
can occur to patients [8]. The reduction of medications and medication discrepancies
istic regression Multivariate logistic regression
I) p-value Odds ratio (95%CI) p-value
0.00496 1.02 (0.99 - 1.04) 0.2475
0.312 1.27 (0.56 - 2.87) 0.5659
0.800466 1.21 (0.15 - 10.33) 0.8579
0.603804 0.80 (0.16 - 3.79) 0.7851
0.492108 0.92 (0.21 - 3.69) 0.9116
0.0496 0.26 (0.07 - 0.89) 0.0366
0.00548 0.28 (0.07 - 1.00) 0.0553
0.242 1.00 (0.74 - 1.48) 0.9825
0.297 0.74 (0.24 - 2.34) 0.602
0.00734 0.89 (0.53 - 1.55) 0.6774
5.51E-06 1.62 (1.31 - 2.06) 3.12E-05
4.65E-08 0.04 (0.01 - 0.11) 1.16E-09
Table 3 Characteristics regarding medication discrepancies
Type of medication discrepancy All groups Standard care arm Intervention arm Value p-value
242 (100) 125 (51.65) 117 (48.35)
Type of discrepancy 97.5313 < 2.2e-16
Incorrect or omitted dose 165 (20.4) 83 (15.7) 82 (29.0)
Therapeutic duplication 5 (0.6) 4 (0.8) 1 (0.3)
Incorrect or omitted frequency 6 (0.7) 6 (1.1) 0 (0.0)
No indication 2 (0.3) 2 (0.4) 0 (0.0)
Drug omission 447 (55.1) 350 (66.3) 97 (34.3)
Too soon to restart drug therapy 26 (3.2) 15 (2.8) 11 (3.9)
Slow to restart drug therapy 156 (19.2) 64 (12.1) 92 (32.5)
Inappropriate route 4 (0.5) 4 (0.8) 0 (0.0)
Number of discrepancies, median (IQR, min, max) 3 (4, 0, 15) 3 (4, 0, 15) 1 (4, 0, 13) 4.3812 1.765e-05
Abbreviations: IQR, interquartile range; in, minimum; max, maximum.
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portance of obtaining accurate and complete medication
histories.
Some studies [5,9,24] have reported that pharmacists
are ideal for supporting a multidisciplinary healthcare team
because of their increased familiarity with medications.
Our results agreed with previous studies which reported
that pharmacists involved in ED admission could increase
medication detection level and identify more medications
per patient than doctors or nurses when noting their
medication history [7,24], i.e. such histories were more
accurate and complete.
Pharmacists used multiple sources for gathering a
complete medication history for proactively issuing
medication orders to support doctors making prescriptions
during ED admission. Dawson et al., [25] have shown that
doctors obtained an average of 79% of the complete drug
history regarding prescription drug use and 45% for over-
the-counter drug use, whereas pharmacists obtained aTable 4 Discrepancy type and potential severity
Type of discrepancy No. Class 1a Class 2b Class 3c
Incorrect or omitted dose 165 39 (23.6) 32 (19.4) 94 (57.0)
Therapeutic duplication 5 4 (80.0) 0 (0.00) 1 (20.0)
Incorrect or omitted frequency 6 0 (0.00) 4 (66.7) 2 (33.3)
Slow to restart drug therapy 156 28 (18.0) 103 (66.0) 25 (16.0)
No indication 2 0 (0.00) 2 (100) 0 (0.00)
Drug omission 447 190 (43.0) 187 (42.0) 70 (15.0)
Too soon to restart drug therapy 26 10 (38.0) 14 (54.0) 2 (8.0)
Inappropriate or omitted route 4 0 (0.00) 4 (100) 0 (0.00)
Total 811 271 (33.4) 346 (42.7) 194 (23.9)
aClass 1: discrepancies unlikely to cause patient discomfort or clinical deterioration.
bClass 2 discrepancies which could cause moderate discomfort or
clinical deterioration.
cClass 3 discrepancies potentially resulting in severe discomfort or
clinical deterioration.100% complete history for both categories of drug use.
Todd et al., [26] has stated that pharmacists documented
significantly more medication doses and dosage schedules
than physicians did (614 cf 446 and 614 cf 404, respectively)
(p ≤ 0.001 for both comparisons) and 614 medications were
identified by pharmacists for the 55 patients interviewed,
compared to 556 identified by doctors (p ≤ 0.001).
In some earlier non-randomised studies of pharmacist-
conducted medication histories and assessment before
admission to an ED [21], the most common type of
discrepancy involved the omission of a medication which a
patient was taking at home (57%); our findings confirmed
such report (55.1%).
Hayes et al., [27] found that allergy documentation was
recorded for 62 patients in a control group (79%) compared
to 60 patients in the study group (100%) (p = 0.001).
Twenty-five patients were identified in our study suffering
from allergies in the intervention arm whilst the standard
care arm identified 23 (p < 0.001). Pharmacists identified
an almost equal number of allergies as did the doctors.
Overall, a reduction in discrepancies was due to interven-
tion, expected clinical conditions (number of medications
being taken) and a particular ED setting. Although the
hospitals participating in the study were selected as they
had very similar general characteristics, it was revealed
that an ED healthcare setting significantly affected the risk
of discrepancies occurring.
The hospitals may have had different results because
staff training/procedures were different and training
admitting physicians and medical students could have had
some impact. Significant barriers often occur regarding
accurate and complete medication information being
obtained during admission related to patients who go
to hospitals due to the differing demographics of the
populations which they serve. The amount and availability
of resources for healthcare attention and the hospitals’
capacity for attending patients could have influenced
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collection.
Evaluating the potential clinical impact of the uninten-
tional discrepancies identified during our study showed
that 23.9% were judged to have had the potential to cause
a patient severe discomfort. Potential harm was driven by
the type of discrepancy (incorrect or omitted dose). An
example would be a patient who was admitted with
cardiac arrhythmia; 150 mg propafenone was ordered by
the ED doctor (R2) because it had been noted during
the first patient interview (R1) that he had been taking
propafenone; however, the ED doctor did not know that
a lower dose had already been ordered by a cardiologist 6
weeks earlier (i.e. based on later scrutiny of the patient’s
record by MedRec staff – R3).
Zed et al., [28] evaluated incidence, severity and prevent-
ability of medication-related visits to an ED, establishing
that severity had been classified as moderate; of all
patients having medication discrepancies at the time of
ED admission in our study, more than two thirds of such
discrepancies had the potential to cause moderate harm.
The number of patients having at least one interaction
was very high (36.8%), compared to studies elsewhere [29].
This could have been related to different definitions or
prescribing practice. Further analysis is required for identi-
fying what might have motivated the above differences
(our group is currently working on an adverse-events-
based paper to extend this line of research). Interactions
do not always represent contraindications for use, but
knowledge and an appreciation of them before prescrip-
tion is essential for the safe use of medication. This
should thus be considered when a doctor decides to
continue with a set prescription after evaluating any
possible interaction.
It was estimated that a pharmacist would have to spend
29.5 minutes per patient to provide this service for
patients in a similar ED. However, such calculation
was based on uninterrupted work-flow times and may
have underestimated the actual time required outside a
research setting. A consultation with just a pharmacist in
an ED focusing on a medication list may be a solution.
Models maximising the use of a pharmacist should be
evaluated in future research.
This study had several limitations. Despite the study
being conducted in teaching hospitals, the results may not
be generalised to other settings because an ED setting was
a factor regarding the risk of a discrepancy appearing.
Future research could examine the effect of ED admission
setting and blocking; a cluster study should thus be
carried out.
It is acknowledged that the validity of any method
for scoring medication discrepancy is difficult to assess
because there is currently no gold standard for compari-
son. A reconciled history (F3) should provide the goldstandard for identifying home medication use; however,
this could have been a limitation of this study. Patient or
caregiver reports were relied on, in conjunction with
collateral information from medication vials whenever
possible.
Error rates may differ regarding services other than an
ED concerning admissions which are elective or involve
a transfer from another healthcare facility, or concerning
patients taking more than 1 medication. Our findings
may not have been representative of other institutions using
processes different to MedRec for admission. Eligible
patients were not followed-up beyond the study; thus,
we are not aware of the effect of such ED admission
process on medical outcomes.
The rating method used for assessing the potential
severity of the discrepancies and F1 questionnaire used
during a medication history interview has not been
validated. Inter-rater agreement was also not evaluated
as interviewing the same patient twice could have led to
recall bias.
The hospitals involved in this study are developing a
MedRec pathway which will incorporate some strategies
based on the present study’s findings. The next phase
will involve an assessment of medication discrepancies once
the new MedRec protocol is in place. The data presented
herein has suggested that recording medication histories
on admission could be improved. Future research could
involve a cost-benefit analysis of the intervention for
implementing such initiative.Conclusions
To improve patient care and minimise unintended
discrepancies in an ED, the healthcare system should
explore ways for involving a pharmacist as part of the
multidisciplinary team to improve ED admission medica-
tion history accuracy thereby improving patient safety
during admission. A pharmacist-acquired medication
history in an ED focusing on a patient’s current home
medication regimen available to be used by a doctor at
the time of consulting in an ED reduced the number of
patients having at least 1 medication discrepancy related
to home medication.Ethics approval
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